David MARGOLIS, University of North Carolina, Chapel Hill, USA
“The experience of the Berlin patient showed the world that HIV can be cured. The oncology drug vorinostat has been shown to awaken latent HIV from latency. Work is now ongoing to develop safe and effective ways to purge HIV genomes that persistent despite therapy, and arm the immune system to destroy the last vestiges of HIV infection. Tools to eradicate established HIV infection will be a key part of reaching an AIDS-free world.”
David Margolis, MD is a professor of Medicine, Microbiology & Immunology, and Epidemiology at the University of North Carolina at Chapel Hill. A graduate of Tufts University School of Medicine, he trained in medicine at the New England Medical Center, infectious diseases at the NIAID, and did post-doctoral research in the regulation of HIV gene expression at the University of Massachusetts Program in Molecular Medicine. His laboratory studies interactions between HIV and the host cell on the molecular level, with an eye to use these insights to improve the treatment of HIV infection, and the management of the HIV pandemic. Current work focuses on the molecular mechanisms that control the latent reservoir of HIV infection within resting T cells. The group has described selected members of the family of chromatin modifying enzymes, histone deacetylases, which act at the proviral promoter to enforce latency. The laboratory is attempting to test novel reagents that perturb latency in T cells obtained from HIV-infected patients, followed by clinical experiments that attempt to deplete persistent HIV infection and develop the tools needed to cure HIV infection.
Dr. Margolis is a member of the editorial board of the Journal of Virology, and a member of the American Society of Clinical Investigation, and a fellow of the American College of Physicians and the Infectious Diseases Society of America, and the principal investigator of the NIH-sponsored Collaboratory of AIDS Researchers for Eradication (CARE).
« Go Back